HHS has taken action to expand access to six peptides that were key in a controversial meeting this summer.
The interim enforcement policy states that, based on the Pharmacy Compounding Advisory Committee (PCAC) meeting that took place in July, “HHS believes that there is significant interest in the use of these peptides in compounding.” So, in an effort “to expand and improve patient access while FDA reviews these substances,” HHS will not take action against physicians, state-licensed pharmacies or federal facilities compounding a drug using the following bulk drug substances on the 503A